| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Healthwell Acquisition Corp. I (0001845013) (Issuer)
15-12G - Healthwell Acquisition Corp. I (0001845013) (Filer)
25-NSE - Healthwell Acquisition Corp. I (0001845013) (Subject)
8-K/A - Healthwell Acquisition Corp. I (0001845013) (Filer)
8-K - Healthwell Acquisition Corp. I (0001845013) (Filer)
DEF 14A - Healthwell Acquisition Corp. I (0001845013) (Filer)
425 - Healthwell Acquisition Corp. I (0001845013) (Subject)
8-K - Healthwell Acquisition Corp. I (0001845013) (Filer)
PRE 14A - Healthwell Acquisition Corp. I (0001845013) (Filer)
425 - Healthwell Acquisition Corp. I (0001845013) (Subject)
8-K - Healthwell Acquisition Corp. I (0001845013) (Filer)
Fastest customizable press release news feed in the world
Healthwell Acquisition Corp. I ("Healthwell") (NASDAQ:HWEL) announced today that (i) its previously announced special meeting of stockholders that was scheduled for December 4, 2023 has been cancelled, and that it has withdrawn from consideration by Healthwell's stockholders the proposals set forth in Heatlhwell's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2023 and (ii) it intends instead to liquidate. The board of directors of Healthwell (the "Board") has determined to (i) cease all operations except for the purpose of winding up as soon as practicable, (ii) as promptly as reasonably possible redeem the sh
Healthwell Acquisition Corp. I ("Healthwell") (NASDAQ:HWEL) announced today that its previously announced Business Combination Agreement in connection with its planned business combination with Starton Therapeutics, Inc. ("Starton") was terminated by Starton. The conditions to the closing of the initial business combination were not satisfied or waived by the outside date of November 3, 2023. As a result, Healthwell will seek an alternative business combination. About Healthwell Healthwell is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
Starton Therapeutics Inc. ("Starton" or "the Company"), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced that it notified Healthwell Acquisition Corp. I (NASDAQ:HWEL) ("Healthwell") today that the Company had elected to terminate the business combination agreement among Starton, Healthwell and the other parties thereto dated as of April 27, 2023, as amended (the "Combination Agreement"), effective immediately. The conditions to the closing of the initial business combination and subsequent amendments were not satisfied or waived by the outside date of November 3 2023 (the "Termination"). As a
Healthwell Acquisition Corp. I ("Healthwell," "HWEL" or the "Company") (NASDAQ:HWEL) announced today that it has postponed until further announcement the date of the special meeting of the Company's stockholders (the "Meeting") to approve its proposed business combination with Starton Therapeutics, Inc. ("Starton") and related transactions that had been scheduled for 10:00 a.m. Eastern Time on October 25, 2023. At the Meeting, the stockholders will vote on the proposals set forth in Healthwell's proxy statement/prospectus dated October 2, 2023 and filed with the Securities and Exchange Commission to approve the business combination with Starton and related proposals described therein (colle
Healthwell Acquisition Corp. I ("Healthwell," "HWEL" or the "Company") (NASDAQ:HWEL) announced today that it has postponed the date of the special meeting of the Company's stockholders (the "Meeting") to approve its proposed business combination with Starton Therapeutics, Inc. ("Starton") and related transactions from the originally scheduled date of October 19, 2023. The new Meeting time and date will be 10:00 a.m. Eastern Time on October 25, 2023 and will be held virtually. At the Meeting, the stockholders will vote on the proposals set forth in Healthwell's proxy statement/prospectus dated October 2, 2023 and filed with the Securities and Exchange Commission to approve the business combi
Dosing comes three weeks after the first site opened Full enrollment of six patients is expected to take 10 months, conducted in up to three clinical sites Multiple readings for safety and efficacy are expected during the next 6 to 18 months Starton Therapeutics Inc. ("Starton" or "the Company"), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced the dosing of the first patient in the STAR-LLD Phase 1b clinical trial, which will assess the safety, efficacy and pharmacokinetics of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) for the treatment of multiple m
Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Site activation comes several months ahead of schedule, significantly accelerating Starton's clinical program timeline Starton Therapeutics Inc. ("Starton" or "the Company"), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced Gabrail Cancer Center (GCC) in Canton, Ohio as the first site activated in the STAR-LLD Phase 1b clinical trial. Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study's lead investigator. This press release features multimedia. V
Nash Gabrail, MD of the Gabrail Cancer Center to be lead investigator Start-up services are underway with patient enrollment planned for Q4 2023 Starton Therapeutics Inc. ("Starton" or "the Company"), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today entered into a definitive agreement to conduct its Phase 1b trial in multiple myeloma with a global Clinical Research Organization (CRO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230710666066/en/ This pilot, open-label study will evaluate patients treated with continuously del
FDA agrees to the planned Phase 1b study in second-line transplant-ineligible patients in multiple myeloma Treatment regimen will include Velcade® (bortezomib) and dexamethasone and replace oral Revlimid® with STAR-LLD Starton Therapeutics Inc. ("Starton" or "the Company"), a clinical stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today provided updates on its Phase 1b STAR-LLD clinical trial of its investigational continuous delivery lenalidomide in multiple myeloma. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230612747752/en/ The U.S. Fo
Starton Therapeutics, Inc. ("Starton" or "the Company"), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, and Healthwell Acquisition Corp. I (NASDAQ:HWEL) ("Healthwell"), a special purpose acquisition company, today announced that the leadership of Starton and Healthwell will present at the Jefferies Healthcare Conference on June 8th at 11:00 a.m. ET. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230606005552/en/ As previously announced, on April 27, 2023, Starton and Healthwell entered into a definitive business combination agreement with
This live feed shows all institutional transactions in real time.
SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13D - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13G - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13G - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)
SC 13G - Healthwell Acquisition Corp. I (0001845013) (Subject)